Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma

Maarja‐Liisa Nairismägi(National Cancer Centre Singapore), Jing Tan(Genome Institute of Singapore)
Leukemia
February 2, 2018
Cited by 57


Related Papers